---
title: "Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293369455.md"
description: "TD Cowen analyst Ritu Baral reiterated a Buy rating on Palvella Therapeutics (PVLA) with a $267 price target. Baral, a top 100 analyst, covers the healthcare sector. The stock currently holds a Strong Buy consensus among analysts, with an average price target of $235.40."
datetime: "2026-07-21T16:26:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293369455.md)
  - [en](https://longbridge.com/en/news/293369455.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293369455.md)
---

# Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst

In a report released today, Ritu Baral from TD Cowen reiterated a Buy rating on Palvella Therapeutics, with a price target of $267.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Baral is a top 100 analyst with an average return of 44.2% and a 54.84% success rate. Baral covers the Healthcare sector, focusing on stocks such as Insmed, Palvella Therapeutics, and Atai Beckley N.V..

Palvella Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $235.40.

### Related Stocks

- [PVLA.US](https://longbridge.com/en/quote/PVLA.US.md)
- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)

## Related News & Research

- [High-Risk Warning for Investors in Palvella Therapeutics Securities](https://longbridge.com/en/news/294921758.md)
- [Palvella Therapeutics CEO joins Canaccord Genuity Growth Conference fireside chat](https://longbridge.com/en/news/294958978.md)
- [Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)](https://longbridge.com/en/news/295099820.md)
- [Viridian Therapeutics (VRDN) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/295146399.md)
- [Palvella Therapeutics CSO Jeff Martini presents at FDA drug repurposing workshop](https://longbridge.com/en/news/294358691.md)